Bill Lundberg, Merus' president and CEO. For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye, as the company talks up its ...
Bristol Myers Squibb has reached for its wallet to avoid being left behind in the race to develop a new class of bispecific antibodies for cancer that have been billed as the next big thing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback